Madrigal Pharmaceuticals (MDGL) Non-Current Deffered Revenue (2010)

Madrigal Pharmaceuticals' (MDGL) quarterly Non-Current Deffered Revenue came in at $2.2 million in Q4 2010.

Madrigal Pharmaceuticals (MDGL) Non-Current Deffered Revenue (2010) Analysis & Trends

Madrigal Pharmaceuticals (MDGL) has 1 years of Non-Current Deffered Revenue data on file, last reported at $2.2 million in Q4 2010.

On a quarterly basis, Non-Current Deffered Revenue changed N/A year-over-year to $2.2 million in Q4 2010; TTM through Dec 2010 was $2.2 million, a N/A change from a year earlier, with the FY2010 full-year figure at $2.2 million, changed N/A from the prior year.
Non-Current Deffered Revenue for Q4 2010 stood at $2.2 million.
Over the last five years, Non-Current Deffered Revenue for MDGL reached as high as $2.2 million in Q4 2010 and fell as low as $2.2 million in Q4 2010.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Deffered Revenue (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	225.10 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Madrigal Pharmaceuticals	15.77 Bn	15.54 Bn	-	-

Download Data

Date	Value
Dec 31, 2010	2.16 Mn